Phaseline

Companies › Curium US

Curium US: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Oncology; next expected readout Feb 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
177Lu-PSMA-I&T
Lutetium-177 labeled PSMA-targeting radioligand therapy
PSMAPhase 3Metastasis From Malignant Tumor of Prostate; Prostate CancerFeb 2029
Copper Cu 64 PSMA I&T
Cu-64 labeled PSMA-targeting radiopharmaceutical for PET imaging
FOLH1Phase 3Prostate Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06235151Copper Cu 64 PSMA I&TPhase 3Prostate CancerOncologyOct 2026
NCT04886986177Lu-PSMA-I&TPhase 1Prostate CancerOncologyDec 2027
NCT05204927177Lu-PSMA-I&TPhase 3Metastasis From Malignant Tumor of ProstateOncologyFeb 2029

Targets

PSMA (1) FOLH1 (1)

Companies with the same targets

Clarity Pharmaceuticals Novartis Fusion Pharmaceuticals C Ray Therapeutics Johnson & Johnson (Janssen) Telix Pharmaceuticals (Innovations) Nova Therapeutics Eli Lilly Lantheus Medical Imaging Sinotau Pharmaceutical Group

Companies built like this

Clarity Pharmaceuticals Fusion Pharmaceuticals POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company ABX advanced biochemical compounds FutureChem

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.